AU Patent

AU2019203505A1 — Improved compositions for treating muscular dystrophy

Assigned to Sarepta Therapeutics Inc · Expires 2019-06-06 · 7y expired

What this patent protects

C:\Interwovn\NRPortbl\DCC\SXD\18832357 l.DOCX-16/05/2019 Improved compositions and methods for treating muscular dystrophy by administering an antisense molecule such as eteplirsen, capable of binding to a selected target site in the human dystrophin gene to induce exon skipping,…

USPTO Abstract

C:\Interwovn\NRPortbl\DCC\SXD\18832357 l.DOCX-16/05/2019 Improved compositions and methods for treating muscular dystrophy by administering an antisense molecule such as eteplirsen, capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, are described.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019203505A1
Jurisdiction
AU
Classification
—
Expires
2019-06-06
Drug substance claim
No
Drug product claim
No
Assignee
Sarepta Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.